NR-15775结核分枝杆菌、CDC1551、转座子突变体敲除池3(突变细菌)
产品图片
货号/SKU
NR-15775
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质,其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类:美国、3
产品描述信息
NR-15775??Mycobacterium tuberculosis, CDC1551, Transposon Mutant Knock-Out Pool 3(Mutant Bacteria)|Mycobacterium tuberculosis|CDC1551, Transposon Mutant Knock-Out Pool 3|-60°C or colder|WR BishaiAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Mycobacterium tuberculosis, Strain CDC1551, Transposon Mutant Knock-Out Pool 3, NR-15775."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
In 2002, TARGET (Tuberculosis Animal Research and Gene Evaluation Taskforce) was formed to enable the modeling of human tuberculosis in multiple animal species using defined protocols and testing defined mutants of Mycobacterium tuberculosis (M. tuberculosis). In addition to animal modeling activities, a library of intragenic transposon mutants has been created and characterized.
There are 20 transposon mutant knock-out pools available from BEI Resources (NR-15773 to NR-15792) that are companion products to the DeADMAn DNA Microarray (available from BEI Resources as NR-18958). The DeADMAn DNA Microarray is used for identification of genes essential for the survival of a stress condition in an in vivo model system infection.
M. tuberculosis, strain CDC1551 transposon mutant knock-out pool 3 is reported to be a mixture of 20 genetically defined M. tuberculosis transposon mutants. Some of the transposon mutants in knock-out pool 3 are available individually (see Pool 3 components below).
Each vial contains approximately 1 mL of bacterial culture in Middlebrook 7H9 broth with OADC enrichment containing 100 ?g/mL cycloheximide and 20 ?g/mL kanamycin.
Components:
In 2002, TARGET (Tuberculosis Animal Research and Gene Evaluation Taskforce) was formed to enable the modeling of human tuberculosis in multiple animal species using defined protocols and testing defined mutants of Mycobacterium tuberculosis (M. tuberculosis). In addition to animal modeling activities, a library of intragenic transposon mutants has been created and characterized.
There are 20 transposon mutant knock-out pools available from BEI Resources (NR-15773 to NR-15792) that are companion products to the DeADMAn DNA Microarray (available from BEI Resources as NR-18958). The DeADMAn DNA Microarray is used for identification of genes essential for the survival of a stress condition in an in vivo model system infection.
M. tuberculosis, strain CDC1551 transposon mutant knock-out pool 3 is reported to be a mixture of 20 genetically defined M. tuberculosis transposon mutants. Some of the transposon mutants in knock-out pool 3 are available individually (see Pool 3 components below).
Each vial contains approximately 1 mL of bacterial culture in Middlebrook 7H9 broth with OADC enrichment containing 100 ?g/mL cycloheximide and 20 ?g/mL kanamycin.
Components:
Description of Transposon Knock-Out Mutant | Strain CDC1551 Gene | Strain H37Rv Gene1 | BEI Resources Product Number2 |
---|---|---|---|
CONSERVED HYPOTHETICAL PROTEIN | MT3085 | Rv3005c | NA |
PROBABLE CONSERVED INTEGRAL MEMBRANE PROTEIN | MT0119 | Rv0110 | NA |
PE-PGRS FAMILY PROTEIN | MT2812 | Rv2741 | NR-15040 |
PROBABLE MONOOXYGENASE | MT3134 | Rv3049c | NR-15041 |
POSSIBLE RNA METHYLTRANSFERASE | MT2178 | Rv2118c | NA |
POSSIBLE LIPOPROTEIN | MT1593 | Rv1541c | NR-15434 |
PROBABLE INTEGRASE/RECOMBINASE | MT2962 | Rv2894c | NA |
PROBABLE CONSERVED INTEGRAL MEMBRANE PROTEIN | MT2945 | Rv2877c | NR-15043 |
PROBABLE ACETOLACTATE SYNTHASE | MT3613 | Rv3509c | NR-18239 |
HYPOTHETICAL PROTEIN | MT1560 | Rv* | NA |
PROBABLE GLYCEROL-3-PHOSPHATE DEHYDROGENASE [NAD(P)+] | MT3060 | Rv2892c | NA |
CONSERVED HYPOTHETICAL PROTEIN | MT1247 | Rv1209 | NA |
CONSERVED HYPOTHETICAL PROTEIN | MT1937 | Rv1889c | NR-15044 |
PROBABLE EXONUCLEASE V, ALPHA SUBUNIT | MT0657 | Rv0629c | NR-15045 |
CONSERVED HYPOTHETICAL PROTEIN | MT1884 | Rv1836c | NA |
POSSIBLE EXPORTED PROTEIN | MT0213 | Rv0203 | NA |
PROBABLE CONSERVED TRANSMEMBRANE PROTEIN | MT0981 | Rv0954 | NA |
POSSIBLE TRANSCRIPTIONAL ACTIVATOR PROTEIN | MT1500 | Rv1453 | NR-15046 |
RECOMBINASE A, INTEIN-CONTAINING | MT2806 | Rv2737c | NR-15047 |
CONSERVED HYPOTHETICAL PROTEIN | MT2261 | Rv2205c | NR-15048 |
1Rv* - In some cases there is no M. tuberculosis, strain H37Rv homologue to the M. tuberculosis, strain CDC1551 gene | |||
2NA - Individual transposon mutant not available from BEI Resources but may be available from TARGET |
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.通过此限制的订单将在发货前发送到NIAID进行批准. target (结核病动物研究和基因评估任务)形成为使用定义的方案和测试分枝杆菌(结核病)的定义的突变体来实现多种动物物种中的人结核病建模.除了动物建模活动外,还创建和表征了一种腺体转座子突变体. 有来自BEI资源(NR-15773至NR-15792)的20名转座突变体敲除池产品到Deadman DNA微阵列(可从BEI资源获得NR-18958).死亡DNA微阵列用于鉴定在体内体内系统感染中的胁迫条件的生存基因所必需的基因. m.结核病,菌株CDC1551转座子突变突变池3被据报道为20种遗传定义的 m的混合物.结核病转座突变体.敲除池3中的一些转座突变体可单独使用(参见下面的池3个组分). 每个小瓶中含有大约1ml的中间细菌培养物,含有100μg/ ml环己酰胺的OADC富集和20μg/ ml kanamycin. .customtable {border:0px;单元填充:5px;细胞间距:5px;}.定制TD,TH {边框:0PX;垂直对齐:底部;}#col1 {text-align:left;宽度:70%;}#col2 {text-align:center;宽度:10%;}#col3 {text-align:center;宽度:10%;}#col4 {text-align:center;宽度:10%;} 转座子敲除突变体的描述 菌株 cdc1551 基因 菌株 基因 1 bei资源产品 2 保守假设蛋白 mt3085 Rv3005c na 可能保守的整体膜蛋白 mt0119 RV0110 NA PE-PGR系列蛋白 mt2812 rv2741 nr-15040 可能的单氧基酶 mt3134 rv3049c nr-15041 可能的RNA甲基转移酶 mt2178 rv2118c na 可能的脂蛋白 mt1593 rv1541c nr-15434 可能集成酶/重组酶 mt2962 rv2894c Na 可能保守的整体膜蛋白 MT2945 rv2877c NR-15043 可能acetoleate合成酶 MT3613 rv3509c nr-18239 假设蛋白 mt1560 RV * na 可能甘油-3-磷酸脱氢酶[nad(p)+] mt3060 rv2892c na 保守假设蛋白 MT1247 RV1209 NA 保守假设蛋白 mt1937 RV1889C nr-15044 可能的外切核酸酶V,alpha子单元 MT0657 RV0629C NR-15045 保守假设蛋白 mt1884 rv1836c na 可能的导出蛋白 mt0213 rv0203 na 可能保守跨膜蛋白 MT0981 RV0954 NA 可能的转录激活蛋白 mt1500 RV1453 nr -15046 重组酶a,含Intein的 mt2806 rv2737c NR-15047 缺点已经假设的假设蛋白 mt2261 Rv2205c 1 rv * - 在某些情况下,没有 m.结核病,菌株H37RV同源物至 m.结核病,菌株CDC1551基因 2 na - 从BEI资源不提供的单个转座子突变体,但可以从 target
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立,旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中,可以监控科学界对这些材料的访问和使用,并确保试剂的质量控制。
除了为传染病界提供材料外,BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势,包括安全存储、社区访问和分发;同时保护存款人的知识产权。只要有需要,BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月, ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料,包括由其他政府支持的研究项目存放的材料,将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中,涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2021-12-21
2024-01-21
2021-12-21
2022-04-01
2021-12-21
2020-06-09
2024-05-19
2020-08-04
2022-04-01
2022-04-01
2024-08-16
2022-04-01
2022-01-10
2021-12-21
2022-04-01
2022-04-01